What are Eli Lilly's main revenue-generating products and their patent protection status?

Eli Lilly's key products include Zyprexa (neuroscience), Gemzar (oncology), Humalog (endocrine), Evista (endocrine), and Actos (endocrine). Compound patent expirations in the U.S. are noted for Zyprexa in 2011, Humalog in 2013, and ReoPro in 2015. Method-of-use and formulation patents, along with potential patent term extensions, are crucial for extending exclusivity beyond the compound patent expiry for products like Gemzar (2010/2012), Evista (at least 2012), Xigris (until 2015), Strattera (until 2016), Cialis (until 2017), Alimta (expected until 2016), and Cymbalta (2008/2013/2014).

What significant legal and regulatory risks does Eli Lilly face?

Eli Lilly faces substantial legal risks including patent litigation from generic manufacturers challenging key patents for Zyprexa and Evista. Product liability lawsuits are significant, particularly those concerning Zyprexa, alleging injuries like diabetes and associated promotional misconduct. Additionally, investigations into marketing and promotional practices for Evista, Zyprexa, Prozac, and Prozac Weekly by the Department of Justice and SEC pose a material risk. The company also faces environmental liabilities and other litigation.

How is Eli Lilly investing in future growth and what is its R&D strategy?

Eli Lilly invests heavily in research and development, with expenses totaling $2.69 billion in 2004. The company has narrowed its research focus to four core therapeutic categories: central nervous system diseases, endocrine diseases (including diabetes and osteoporosis), cancer, and cardiovascular diseases. It also engages in biotechnology research, genomics, and biomarkers. The strategy includes internal discovery, external collaborations with academic and industry partners, licensing, co-development, and acquisitions to complement its R&D pipeline. Development is ongoing for potential therapies in diabetes, osteoporosis, cancer, and acute coronary syndromes, among other areas.

What is the company's outlook regarding competition and pricing pressures?

Eli Lilly operates in highly competitive markets and anticipates increasing pricing pressures, particularly in the U.S. due to the Medicare Prescription Drug, Improvement and Modernization Act (MMA) and continued state-level cost containment measures. The expiration of patents on key products exposes them to intense price competition from generic manufacturers. In international markets, price controls and other cost-containment measures are also prevalent. The company's long-term competitiveness relies on discovering and developing innovative, cost-effective products.

LLY 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 2004 10-K filing highlights a robust pharmaceutical business centered on innovative drug discovery and development across key therapeutic areas such as neuroscience, endocrine, oncology, and cardiovascular diseases. The company's success is heavily reliant on its ability to continuously bring new products to market and protect its intellectual property. Significant new product launches in 2004, including Cymbalta, Alimta, and Yentreve, signal a pipeline that is translating into commercial success. However, the filing also underscores considerable risks, particularly concerning patent expirations, increasing competition from generic manufacturers, and ongoing legal and regulatory challenges. The company is actively defending its patents for key products like Zyprexa and Evista against Paragraph IV certifications. Furthermore, Eli Lilly is navigating a complex landscape of government regulation, pricing pressures, and investigations into marketing practices, which could materially impact future financial performance.

Key Highlights

1Eli Lilly operates primarily in the pharmaceutical segment, with a strong focus on research and development for innovative treatments across neuroscience, endocrine, oncology, and cardiovascular diseases.

2The company launched several new products in 2004, including Cymbalta for depression and neuropathic pain, Alimta for mesothelioma and lung cancer, and Yentreve for urinary incontinence in the EU, indicating pipeline progression.

3Significant dependence on a few key products, with Zyprexa, Gemzar, Humalog, Evista, and Actos being central to its portfolio, and their patent expirations (ranging from 2010-2011 for compound patents) present a material risk.

4The company is facing numerous legal challenges, including patent litigation against generic manufacturers for Zyprexa and Evista, and significant product liability lawsuits related to Zyprexa.

5Marketing and promotional practices are under scrutiny by various government agencies, with ongoing investigations into Zyprexa, Prozac, and Evista, potentially leading to material adverse effects.

6Research and development expenses were substantial at $2.69 billion in 2004, underscoring the company's commitment to innovation but also representing a significant investment with uncertain outcomes.

7The company is proactively managing market risks, including foreign exchange fluctuations through hedging, and is adapting to changes in healthcare policy like the Medicare Prescription Drug, Improvement and Modernization Act (MMA).

Frequently Asked Questions